HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Peyrot, M. Articles by Rubin, R. R. Search for Related Content PubMed PubMed Citation Articles by Peyrot, M. Articles by Rubin, R. R. Social Bookmarking                What's this?

Validity and Reliability of an Instrument for Assessing Health-Related Quality of Life and Treatment Preferences

The Insulin Delivery System Rating Questionnaire

¹ Department of Sociology and Center for Social and Community Research, Loyola College, Baltimore, Maryland
² Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
³ Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland

Address correspondence and reprint requests to Mark Peyrot, PhD, Center for Social and Community Research, Loyola College, 4501 North Charles St., Baltimore, MD 21210-2699. E-mail: mpeyrot{at}loyola.edu

OBJECTIVE—To provide a preliminary assessment of the validity and reliability of a new measure of health-related quality of life (HRQOL) and treatment preference for insulin delivery systems.

RESEARCH DESIGN AND METHODS—Study participants were 197 adults with type 1 or type 2 diabetes who completed the Insulin Delivery System Rating Questionnaire (IDSRQ), a self-administered questionnaire developed for this study. The IDSRQ assessed patient perceptions of treatment satisfaction, impact of treatment on daily activities, clinical efficacy, diabetes-related worries and social burdens, psychological well-being, and overall treatment system preference of patients using continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI).

RESULTS—The IDSRQ subscales had acceptable reliability ( = 0.67–0.92, median 0.82) and test-retest correlations (intraclass correlation coefficient 0.67–0.94, median 0.88). Floor effects (0–10%, median 0%) and ceiling effects (0–18%, median 4%) were minimal. There were statistically significant differences (P < 0.05) between patients using CSII and MDI on all IDSRQ subscales except psychological well-being (P = 0.096); differences in means were 0.3–1.4 SD units (median 0.9). Multiple regression analysis (controlling for age, sex, and type of diabetes) showed that treatment satisfaction, perceived clinical efficacy, and psychological well-being were independently associated with overall treatment preference and accounted for half of the difference in preference between CSII and MDI patients.

CONCLUSIONS—Preliminary findings suggest that the IDSRQ is a valid and reliable measure of HRQOL and treatment preferences for insulin delivery systems. The subscales are comprehensive, sensitive to differences in user populations, and account for most of the preference for a particular insulin delivery system.

Abbreviations: CSII, continuous subcutaneous insulin infusion • HRQOL, health-related quality of life • IDSRQ, Insulin Delivery System Rating Questionnaire • MDI, multiple daily injections

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Phillip, T. Battelino, H. Rodriguez, T. Danne, F. Kaufman, and for the Consensus forum participants Use of Insulin Pump Therapy in the Pediatric Age-Group: Consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care, June 1, 2007; 30(6): 1653 - 1662. [Full Text] [PDF]